FACE-OFF: Team Blue vs Team Purple

Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and hemoglobin levels among study participants.

Panelists discuss how the MEDALIST and IMerge trials provide crucial insights into novel therapeutic approaches for treating myelodysplastic syndromes.

Panelists discuss how clinicians should weigh the decision between initiating treatment with erythropoiesis-stimulating agents (ESAs) vs luspatercept in patients with myelodysplastic syndromes.

Panelists discuss how to optimize luspatercept dosing strategies by evaluating the benefits and risks of starting at maximum dose with downward titration vs initiating at lower doses with upward adjustments.

Panelists discuss how to approach patients who show inadequate response to initial erythropoiesis-stimulating agent (ESA) therapy, including assessment strategies and potential next steps in treatment modification.

Panelists discuss how to develop treatment strategies for patients with ring sideroblasts and genetic abnormalities, focusing on the role of specialized therapies and the importance of molecular testing in guiding clinical decisions.